revealed via a mouse model, that the combination of RANKL inhibitor and ICIs significantly increased the number of infiltrating T cells and expression of anti-tumor cytokines (IFN-γ, etc.)in the tumor microenvironment (TME) compared to a single agent, and the combination therapy significantly reduced mouse tumor burden (11, 12). The gene discussed is TNFSF11; the disease is neoplasm.